Kiromic BioPharma, Inc. (5JU0.F)
| Previous close | 3.6450 |
| Open | 3.6450 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.6450 - 4.0995 |
| 52-week range | 0.1300 - 6.9000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 4.822M |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -52.4900 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
HOUSTON, April 24, 2024--Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Business WireKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
HOUSTON, April 02, 2024--Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Business WireEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
HOUSTON, March 19, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
